Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Estybon (rigosertib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Knight Therap, Pint Pharma, Specialised Therap, SymBio Pharma, Traws Pharma

Drug class:

PI3K inhibitor, PLK1 inhibitor, RAS antagonist

Related drugs:

PF-05212384 (31)

GSK2126458 (17)

PF-04691502 (6)

enzastaurin (3)

BAY 1082439 (1)

inhibitors of the PI3K/AKT/mTOR pathway (0)

›

KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C2 – Inclusion Criteria nivolumab + rigosertib Sensitive : C2	nivolumab + rigosertib Sensitive: C2 – Inclusion Criteria nivolumab + rigosertib Sensitive : C2
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D
PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D